On December 21, 2022 NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported that it has ended the liquidity contract signed on October 23, 2012 with Gilbert Dupont (Press release, Nanobiotix, DEC 21, 2022, View Source [SID1234625492]). The termination is effective from December 20th, 2022, after the close of Euronext market.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the termination date of this contract, the following assets appeared on the liquidity account:

22,118 shares
€71,489.96 in cash
As a reminder, for the latest half-year statement as of June 30, 2022, the following assets appeared on the liquidity account:

25,706 shares
€ 60,051.07 in cash
And between July 1, 2022, and December 20, 2022, included:

Buy side Traded volume:
303,404 shares € 1,157,145.04 1,274 transactions
Sell side Traded volume:
306,992 shares € 1,168,583.92 990 transactions
Upon initiation of the liquidity contract, the following assets were made available:

0 share
€ 300,000.00 in cash